Jazz Pharmaceuticals Plc - Company Profile
Powered by 
All the sales intelligence you need on Jazz Pharmaceuticals Plc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Jazz Pharmaceuticals Plc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Jazz Pharmaceuticals Plc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Jazz Pharmaceuticals Plc (Jazz Pharmaceuticals) is a specialty biopharmaceutical company that identifies, develops, and commercializes medicines with a focus on narcolepsy, cancer, pain, and psychiatry. Its marketed products include Epidiolex (cannabidiol), Xyrem (sodium oxybate) oral solution, Xywav (calcium, magnesium, potassium, and sodium oxybate) oral solution, Defitelio (defibrotide sodium), Vyxeos (daunorubicin and cytarabine) liposome for injection, and others. It sells products through a network of local distributors and wholesalers. The company also has various pipeline product candidates related to focus areas such as sleep, neurological disorders, hematology, and oncology, including hematologic malignancies and solid tumors. The company has operations in the US and Europe. Jazz Pharmaceuticals is headquartered in Dublin, Ireland.
Headquarters
Ireland
Address
Fifth Floor Waterloo Exchange, Waterloo Road, Dublin, D04E5W7
Website
www.jazzpharma.com
Telephone
353 163 47800
No of Employees
2,890
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
JAZZ (NASD)
Revenue (2024)
$4.3B
4.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-163.6%
(2024 vs 2023)
Market Cap*
$15.5B
Net Profit Margin (2024)
XYZ
-160.6%
(2024 vs 2023)
* As of and is in US$
Jazz Pharmaceuticals Plc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Sodium Oxybate Oral Solution | Epidiolex |
| Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution | Sativex |
| Cannabidiol | Xyrem |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Others | In January, the company divested a priority review voucher for US$200 million. |
| 2025 | Divestiture | In October, the company sold its global Sativex (nabiximols) business to CNX Therapeutics, a pharmaceutical company. |
| 2025 | Regulatory Approval | In July, the company secured approval from the European Commission for marketing authorization for Ziihera (zanidatamab). |
Competitor Comparison
| Key Parameters | Jazz Pharmaceuticals Plc | Merck & Co Inc | Amgen Inc | Takeda Pharmaceutical Co Ltd | Teva Pharmaceutical Industries Ltd |
|---|---|---|---|---|---|
| Headquarters | Ireland | United States of America | United States of America | Japan | Israel |
| City | Dublin | Rahway | Thousand Oaks | Chuo-Ku | Tel Aviv |
| State/Province | Dublin | New Jersey | California | Tokyo | Tel Aviv |
| No. of Employees | 2,890 | 75,000 | 31,500 | 47,029 | 31,173 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Bruce C. Cozadd | Chairman | Executive Board | 2012 | 62 |
| Renee D. Gala | President; Chief Executive Officer; Director | Executive Board | 2025 | 54 |
| Philip L. Johnson | Executive Vice President; Chief Financial Officer | Senior Management | 2024 | 62 |
| Neena M. Patil | Chief Legal Officer; Executive Vice President | Senior Management | 2022 | 51 |
| Heidi Manna | Executive Vice President; Chief People Officer | Senior Management | 2018 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer